BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bose M, Mukherjee P. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers. Vaccines (Basel). 2020;8. [PMID: 33167508 DOI: 10.3390/vaccines8040659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Velikova T, Snegarova V, Kukov A, Batselova H, Mihova A, Nakov R. Gastrointestinal mucosal immunity and COVID-19. World J Gastroenterol 2021; 27(30): 5047-5059 [PMID: 34497434 DOI: 10.3748/wjg.v27.i30.5047] [Reference Citation Analysis]
2 Supruniuk K, Czarnomysy R, Muszyńska A, Radziejewska I. Anti-cancer effects of pyrazole-platinum(II) complexes combined with anti-MUC1 monoclonal antibody versus monotherapy in DLD-1 and HT-29 colon cancer cells. Transl Oncol 2022;18:101348. [PMID: 35121220 DOI: 10.1016/j.tranon.2022.101348] [Reference Citation Analysis]
3 Blangé D, Stroes CI, Derks S, Bijlsma MF, van Laarhoven HW. Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102418] [Reference Citation Analysis]
4 Camp FA, Slansky JE. Implications of Antigen Selection on T Cell-Based Immunotherapy. Pharmaceuticals (Basel) 2021;14:993. [PMID: 34681217 DOI: 10.3390/ph14100993] [Reference Citation Analysis]
5 Elberskirch L, Le Harzic R, Scheglmann D, Wieland G, Wiehe A, Mathieu-Gaedke M, Golf HRA, von Briesen H, Wagner S. A HET-CAM based vascularized intestine tumor model as a screening platform for nano-formulated photosensitizers. Eur J Pharm Sci 2021;168:106046. [PMID: 34670122 DOI: 10.1016/j.ejps.2021.106046] [Reference Citation Analysis]
6 Maleki F, Rezazadeh F, Varmira K. MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy. Mol Pharm 2021;18:1842-61. [PMID: 33821638 DOI: 10.1021/acs.molpharmaceut.0c01249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rodrigues JG, Duarte HO, Reis CA, Gomes J. Aberrant protein glycosylation in cancer: implications in targeted therapy. Biochem Soc Trans 2021;49:843-54. [PMID: 33704376 DOI: 10.1042/BST20200763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Supruniuk K, Czarnomysy R, Muszyńska A, Radziejewska I. Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells. Pharmaceutics 2021;13:968. [PMID: 34206951 DOI: 10.3390/pharmaceutics13070968] [Reference Citation Analysis]